Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer

NCT03602586 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

14

Enrollment

NIH

Sponsor class

Conditions

Malignant Ovarian Clear Cell Tumor
Recurrent Ovarian Carcinoma

Interventions

DRUG: Epacadostat
BIOLOGICAL: Pembrolizumab

Sponsor

National Cancer Institute (NCI)

Collaborators

[object Object]